Abo Bibliothek: Guest

Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma

Volumen 2, Ausgabe 2, 2011, pp. 179-188
DOI: 10.1615/ForumImmunDisTher.v2.i2.90
Get accessGet access

ABSTRAKT

Multiple myeloma (MM) is the second most common hematological and incurable malignancy of plasma cells with low proliferative activity in the bone marrow. MM patients initially respond to conventional therapy, however, many develop resistance and recurrences occur. We have identified RKIP as a novel gene product that is differentially overexpressed in MM cell lines and MM tissues compared to other studied tumors and normal bone marrow. This overexpression consisted, in large part, of a phosphorylated inactive form of RKIP at Ser153 (p-Ser153 RKIP). In contrast to RKIP, p-Ser153 RKIP lacks its ability to inhibit the MAPK signaling pathway. The overexpression of p-Ser153 RKIP in MM cell lines and MM tissues was further validated in a mouse model carrying a human MM xenograft, namely, LAGλ-1B. Bioinformatic analyses from databases support the presence of increased RKIP mRNA expression in MM compared to normal plasma cells. In these databases, high RKIP levels in MM are also correlated with the nonhyperdiploid status and the presence of IgH translocations, parameters that generally display more aggressive clinical features and shorter patients’ survival irrespective of the treatment. Since RKIP expression regulates both the NF-κB and MAPK survival pathways, the overexpression of "inactive" p-Ser153 RKIP in MM might contribute positively to the overall cell survival/antiapoptotic phenotype and drug resistance of MM through the constitutive activation of survival pathways and downstream the transcription of anti-apoptotic gene products. The overexpression of RKIP and p-Ser153 RKIP in MM is the first demonstration in the literature, since in most tumor tissues the expression of RKIP is very low and the expression of p-Ser153 RKIP is much lower. The relationship between the levels of active RKIP and inactive p-Ser153 RKIP in MM may be of prognostic significance, and the regulation of RKIP activity may be a target for therapeutic intervention.

REFERENZIERT VON
  1. Li Siwei, Liu Taowen, Mo Wenfa, Hou Qiaoyan, Zhou Yingqiong, Liu Meilian, He Zhoukai, Liu Zhengchun, Chen Qiuqiu, Wang Hua, Guo Xiang, Xia Weixiong, Zeng Musheng, Zhao Haiyun, Prognostic value of phosphorylated Raf kinase inhibitory protein at serine 153 and its predictive effect on the clinical response to radiotherapy in nasopharyngeal carcinoma, Radiation Oncology, 11, 1, 2016. Crossref

  2. Zaravinos Apostolos, Bonavida Benjamin, Chatzaki Ekaterini, Baritaki Stavroula, RKIP: A Key Regulator in Tumor Metastasis Initiation and Resistance to Apoptosis: Therapeutic Targeting and Impact, Cancers, 10, 9, 2018. Crossref

  3. Yesilkanal Ali, Rosner Marsha, Targeting Raf Kinase Inhibitory Protein Regulation and Function, Cancers, 10, 9, 2018. Crossref

  4. Zebisch Armin, Caraffini Veronica, Sill Heinz, RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis, International Journal of Molecular Sciences, 20, 22, 2019. Crossref

  5. Raquel-Cunha Ana, Cardoso-Carneiro Diana, Reis Rui M., Martinho Olga, Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling, Cells, 8, 5, 2019. Crossref

  6. Rama Martina, Bonavida Benjamin, Identification of regulatory crosstalks between RKIP and BRCA1 tumor suppressors in healthy tissues and cancer (breast and ovarian): Therapeutic implications, in Prognostic and Therapeutic Applications of RKIP in Cancer, 2020. Crossref

  7. Touboul Roni, Baritaki Stavroula, Zaravinos Apostolos, Bonavida Benjamin, RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity, Cancers, 13, 24, 2021. Crossref

  8. Lorenz Kristina, Rosner Marsha Rich, Harnessing RKIP to Combat Heart Disease and Cancer, Cancers, 14, 4, 2022. Crossref

  9. Cessna Hannah, Baritaki Stavroula, Zaravinos Apostolos, Bonavida Benjamin, The Role of RKIP in the Regulation of EMT in the Tumor Microenvironment, Cancers, 14, 19, 2022. Crossref

  10. Papale Massimo, Netti Giuseppe Stefano, Stallone Giovanni, Ranieri Elena, Understanding Mechanisms of RKIP Regulation to Improve the Development of New Diagnostic Tools, Cancers, 14, 20, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain